Latest Commercialization News

Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

James Hardie Industries reported a robust 30% jump in Q3 FY26 net sales, driven by the AZEK acquisition and growth in key regions, while operating income declined amid integration costs and market softness.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Commonwealth Bank of Australia’s latest Basel III Pillar 3 disclosures reveal steady capital adequacy ratios and proactive adaptation to evolving regulatory standards as of December 2025.

Ark Mines Limited has signed a pivotal Memorandum of Understanding to trial processing of monazite ore from its Sandy Mitchell Rare Earths Project, aiming to recover critical minerals including Thorium, Neodymium, and Praseodymium.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Electro Optic Systems (EOS) has firmly rejected allegations from a recent Grizzly Research report, highlighting its strengthened financial position, significant contract wins, and strategic acquisition to bolster its defence technology portfolio.

Revolution Private Credit Income Trust has launched a A$60 million institutional placement at A$2.00 per unit, aiming to bolster its investment in senior secured loans across Australia and New Zealand. The trust targets a net yield to maturity of 7.83%, emphasizing disciplined risk management and transparency.